Authors: zur Stadt, U Harms, DO Schluter, S Schrappe, M Goebel, U Spaar, H Janka, G Kabisch, H

Citation: U. Zur Stadt et al., MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen, LEUKEMIA, 15(2), 2001, pp. 283-285

Authors: Brenner, H Kaatsch, P Burkhardt-Hammer, T Harms, DO Schrappe, M Michaelis, J

Citation: H. Brenner et al., Long-term survival of children with leukemia achieved by the end of the second millennium, CANCER, 92(7), 2001, pp. 1977-1983

Authors: Harms, DO Janka-Schaub, GE

Citation: Do. Harms et Ge. Janka-schaub, Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92, LEUKEMIA, 14(12), 2000, pp. 2234-2239

Authors: zur Stadt, U Harms, DO Schluter, S Jorch, N Spaar, HJ Nurnberger, W Volpel, S Gutjahr, P Schrappe, M Janka, G Kabisch, H

Citation: U. Zur Stadt et al., Minimal residual disease analysis in acute lymphoblastic leukemia of childhood after an induction therapy without asparaginase, KLIN PADIAT, 212(4), 2000, pp. 169-173

Authors: Niehues, T Kapaun, P Harms, DO Burdach, S Kramm, C Korholz, D Janka-Schaub, G Gobel, U

Citation: T. Niehues et al., A classification based on T cell selection-related phenotypes identifies asubgroup of childhood T-ALL with favorable outcome in the COALL studies, LEUKEMIA, 13(4), 1999, pp. 614-617

Authors: Janka-Schaub, GE Harms, DO den Boer, ML Veerman, AJP Pieters, R

Citation: Ge. Janka-schaub et al., In vitro drug resistance as independent prognostic factor in study COALL-05-92 for treatment of childhood acute lymphoblastic leukemia: Basis for treatment stratification according to traditional risk factors and drug sensitivity in study COALL-06-97, KLIN PADIAT, 211(4), 1999, pp. 233-238